{"entity":{"type":"insider","cik":"0001429282","url":"/insider/0001429282","json_url":"/insider/0001429282.json","name":"Sanderling VI Limited Partnership","name_source":"as-filed","also_issuer":false,"cross_url":null},"coverage_statement":{"n_transactions":50,"n_filings":12,"first":"2008-08-08","last":"2024-11-05","span_basis":"filed_date"},"name_variants":[{"name":"Sanderling VI Limited Partnership","source":"filing","n_filings":12,"first_seen":"2008-08-08","last_seen":"2024-11-05"}],"transactions":[{"id":2864165,"accession":"0001415889-24-026103","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001415889-24-026103","line_url":"/filing/0001415889-24-026103","is_derivative":false,"issuer_cik":"0001306695","issuer_name":"CalciMedica, Inc.","issuer_ticker":"CALC","issuer_name_source":null,"issuer_url":"/issuer/0001306695","owner_cik":null,"owner_name":"Sanderling Ventures VII (Canada), L.P.; Sanderling VI Beteiligungs GmbH & Co KG; Sanderling Ventures VII Annex Fund, L.P.; Sanderling VI Limited Partnership; Sanderling Ventures VII, L.P.; Sanderling Venture Partners VI LP; Sanderling Ventures Management VI; Sanderling Ventures Management VII","owner_display_name":"Sanderling Ventures VII (Canada), L.P.","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":8,"other_reporting_owners":7,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":87744.0,"shares_display":"87,744","price_per_share":3.75,"price_display":"3.75","price_state":"stated","total_value":329040.0,"total_display":"329,040.00","total_whole":"329,040","shares_owned_after":814300.0,"shares_owned_after_display":"814,300","ownership_form":"D","is_10b5_1":null,"transaction_date":"2024-11-01","filed_date":"2024-11-05","scope":"insider","n_lines":2},{"id":5497030,"accession":"0001104659-13-022694","txn_seq":10,"anchor":"line-10","filing_url":"/filing/0001104659-13-022694","line_url":"/filing/0001104659-13-022694","is_derivative":false,"issuer_cik":"0001267959","issuer_name":"Pacira Pharmaceuticals, Inc.","issuer_ticker":"PCRX","issuer_name_source":null,"issuer_url":"/issuer/0001267959","owner_cik":null,"owner_name":"Sanderling VI Beteiligungs GmbH & Co KG; Sanderling VI Limited Partnership; Sanderling Venture Partners VI Co Investment Fund LP; MIDDLETON FRED A; Sanderling Ventures Management VI; Sanderling Venture Partners VI LP","owner_display_name":"Sanderling VI Beteiligungs GmbH & Co KG","owner_url":null,"role":"Director","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":6,"other_reporting_owners":5,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":84589.0,"shares_display":"84,589","price_per_share":27.271052382697516,"price_display":"27.27","price_state":"stated","total_value":2306831.05,"total_display":"2,306,831.05","total_whole":"2,306,831","shares_owned_after":416083.0,"shares_owned_after_display":"416,083","ownership_form":"D","is_10b5_1":null,"transaction_date":"2013-03-19","filed_date":"2013-03-20","scope":"insider","n_lines":2},{"id":5497025,"accession":"0001104659-13-022694","txn_seq":8,"anchor":"line-8","filing_url":"/filing/0001104659-13-022694","line_url":"/filing/0001104659-13-022694","is_derivative":false,"issuer_cik":"0001267959","issuer_name":"Pacira Pharmaceuticals, Inc.","issuer_ticker":"PCRX","issuer_name_source":null,"issuer_url":"/issuer/0001267959","owner_cik":null,"owner_name":"Sanderling VI Beteiligungs GmbH & Co KG; Sanderling VI Limited Partnership; Sanderling Venture Partners VI Co Investment Fund LP; MIDDLETON FRED A; Sanderling Ventures Management VI; Sanderling Venture Partners VI LP","owner_display_name":"Sanderling VI Beteiligungs GmbH & Co KG","owner_url":null,"role":"Director","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":6,"other_reporting_owners":5,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":165411.0,"shares_display":"165,411","price_per_share":28.687535411792446,"price_display":"28.69","price_state":"stated","total_value":4745233.92,"total_display":"4,745,233.92","total_whole":"4,745,234","shares_owned_after":500672.0,"shares_owned_after_display":"500,672","ownership_form":"D","is_10b5_1":null,"transaction_date":"2013-03-18","filed_date":"2013-03-20","scope":"insider","n_lines":6},{"id":9223240,"accession":"0001104659-13-029502","txn_seq":9,"anchor":"line-9","filing_url":"/filing/0001104659-13-029502","line_url":"/filing/0001104659-13-029502#line-9","is_derivative":false,"issuer_cik":"0001396814","issuer_name":"Pacira Pharmaceuticals, Inc.","issuer_ticker":"PCRX","issuer_name_source":null,"issuer_url":"/issuer/0001396814","owner_cik":null,"owner_name":"MIDDLETON FRED A; Sanderling VI Beteiligungs GmbH & Co KG; Sanderling VI Limited Partnership; Sanderling Venture Partners VI Co Investment Fund LP; Sanderling Venture Partners VI LP","owner_display_name":"MIDDLETON FRED A","owner_url":null,"role":"Director, Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":5,"other_reporting_owners":4,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":348951.0,"shares_display":"348,951","price_per_share":27.86,"price_display":"27.86","price_state":"stated","total_value":9721774.86,"total_display":"9,721,774.86","total_whole":"9,721,775","shares_owned_after":559453.0,"shares_owned_after_display":"559,453","ownership_form":"D","is_10b5_1":null,"transaction_date":"2013-03-11","filed_date":"2013-04-15","scope":"insider"},{"id":4388238,"accession":"0001104659-13-019400","txn_seq":17,"anchor":"line-17","filing_url":"/filing/0001104659-13-019400","line_url":"/filing/0001104659-13-019400#line-17","is_derivative":false,"issuer_cik":"0001306695","issuer_name":"Pacira Pharmaceuticals, Inc.","issuer_ticker":"PCRX","issuer_name_source":null,"issuer_url":"/issuer/0001306695","owner_cik":null,"owner_name":"Sanderling Venture Partners VI LP; Sanderling VI Beteiligungs GmbH & Co KG; Sanderling Venture Partners VI Co Investment Fund LP; Sanderling VI Limited Partnership","owner_display_name":"Sanderling Venture Partners VI LP","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":4,"other_reporting_owners":3,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":348951.0,"shares_display":"348,951","price_per_share":27.86,"price_display":"27.86","price_state":"stated","total_value":9721774.86,"total_display":"9,721,774.86","total_whole":"9,721,775","shares_owned_after":559453.0,"shares_owned_after_display":"559,453","ownership_form":"D","is_10b5_1":null,"transaction_date":"2013-03-11","filed_date":"2013-03-11","scope":"insider"},{"id":9223239,"accession":"0001104659-13-029502","txn_seq":8,"anchor":"line-8","filing_url":"/filing/0001104659-13-029502","line_url":"/filing/0001104659-13-029502","is_derivative":false,"issuer_cik":"0001396814","issuer_name":"Pacira Pharmaceuticals, Inc.","issuer_ticker":"PCRX","issuer_name_source":null,"issuer_url":"/issuer/0001396814","owner_cik":null,"owner_name":"MIDDLETON FRED A; Sanderling VI Beteiligungs GmbH & Co KG; Sanderling VI Limited Partnership; Sanderling Venture Partners VI Co Investment Fund LP; Sanderling Venture Partners VI LP","owner_display_name":"MIDDLETON FRED A","owner_url":null,"role":"Director, Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":5,"other_reporting_owners":4,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":25560.0,"shares_display":"25,560","price_per_share":25.92,"price_display":"25.92","price_state":"stated","total_value":662515.2,"total_display":"662,515.20","total_whole":"662,515","shares_owned_after":1361762.0,"shares_owned_after_display":"1,361,762","ownership_form":"D","is_10b5_1":null,"transaction_date":"2013-03-07","filed_date":"2013-04-15","scope":"insider","n_lines":8},{"id":4388202,"accession":"0001104659-13-019400","txn_seq":8,"anchor":"line-8","filing_url":"/filing/0001104659-13-019400","line_url":"/filing/0001104659-13-019400","is_derivative":false,"issuer_cik":"0001306695","issuer_name":"Pacira Pharmaceuticals, Inc.","issuer_ticker":"PCRX","issuer_name_source":null,"issuer_url":"/issuer/0001306695","owner_cik":null,"owner_name":"Sanderling Venture Partners VI LP; Sanderling VI Beteiligungs GmbH & Co KG; Sanderling Venture Partners VI Co Investment Fund LP; Sanderling VI Limited Partnership","owner_display_name":"Sanderling Venture Partners VI LP","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":4,"other_reporting_owners":3,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":25560.0,"shares_display":"25,560","price_per_share":25.92,"price_display":"25.92","price_state":"stated","total_value":662515.2,"total_display":"662,515.20","total_whole":"662,515","shares_owned_after":908404.0,"shares_owned_after_display":"908,404","ownership_form":"D","is_10b5_1":null,"transaction_date":"2013-03-07","filed_date":"2013-03-11","scope":"insider","n_lines":8},{"id":9223231,"accession":"0001104659-13-029501","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001104659-13-029501","line_url":"/filing/0001104659-13-029501#line-1","is_derivative":false,"issuer_cik":"0001396814","issuer_name":"Pacira Pharmaceuticals, Inc.","issuer_ticker":"PCRX","issuer_name_source":null,"issuer_url":"/issuer/0001396814","owner_cik":null,"owner_name":"MIDDLETON FRED A; SANDERLING VENTURE PARTNERS IV CO INVESTMENT FUND LP; Sanderling VI Beteiligungs GmbH & Co KG; Sanderling VI Limited Partnership; Sanderling Venture Partners VI LP; Sanderling Ventures Management VI","owner_display_name":"MIDDLETON FRED A","owner_url":null,"role":"Director, Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":6,"other_reporting_owners":5,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":500000.0,"shares_display":"500,000","price_per_share":18.93,"price_display":"18.93","price_state":"stated","total_value":9465000.0,"total_display":"9,465,000.00","total_whole":"9,465,000","shares_owned_after":882562.0,"shares_owned_after_display":"882,562","ownership_form":"D","is_10b5_1":null,"transaction_date":"2013-01-24","filed_date":"2013-04-15","scope":"insider"},{"id":4332771,"accession":"0001104659-13-004737","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001104659-13-004737","line_url":"/filing/0001104659-13-004737#line-2","is_derivative":false,"issuer_cik":"0001306695","issuer_name":"Pacira Pharmaceuticals, Inc.","issuer_ticker":"PCRX","issuer_name_source":null,"issuer_url":"/issuer/0001306695","owner_cik":null,"owner_name":"Sanderling Ventures Management VI; Sanderling Venture Partners VI Co Investment Fund LP; Sanderling Venture Partners VI LP; Sanderling VI Beteiligungs GmbH & Co KG; Sanderling VI Limited Partnership","owner_display_name":"Sanderling Ventures Management VI","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":5,"other_reporting_owners":4,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":500000.0,"shares_display":"500,000","price_per_share":18.93,"price_display":"18.93","price_state":"stated","total_value":9465000.0,"total_display":"9,465,000.00","total_whole":"9,465,000","shares_owned_after":882562.0,"shares_owned_after_display":"882,562","ownership_form":"D","is_10b5_1":null,"transaction_date":"2013-01-24","filed_date":"2013-01-25","scope":"insider"},{"id":9268029,"accession":"0001209191-12-003316","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001209191-12-003316","line_url":"/filing/0001209191-12-003316#line-2","is_derivative":false,"issuer_cik":"0001512540","issuer_name":"ENDOCYTE INC","issuer_ticker":"ECYT","issuer_name_source":null,"issuer_url":"/issuer/0001512540","owner_cik":null,"owner_name":"SANDERLING V BETEILIGUNGS GMBH & CO KG; SANDERLING V BIOMEDICAL CO INVESTMENT FUND LP; SANDERLING V BIOMEDICAL LP; SANDERLING V LTD PARTNERSHIP; Sanderling V Strategic Exit Fund LP; Sanderling VI Beteiligungs GmbH & Co KG; Sanderling VI Limited Partnership; Sanderling Venture Partners V Co Investment Fund, LP; Sanderling Venture Partners V, LP; Sanderling Venture Partners VI Co Investment Fund LP","owner_display_name":"SANDERLING V BETEILIGUNGS GMBH & CO KG","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":10,"other_reporting_owners":9,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":197800.0,"shares_display":"197,800","price_per_share":3.16,"price_display":"3.16","price_state":"stated","total_value":625048.0,"total_display":"625,048.00","total_whole":"625,048","shares_owned_after":831461.0,"shares_owned_after_display":"831,461","ownership_form":"I","is_10b5_1":null,"transaction_date":"2011-12-21","filed_date":"2012-01-11","scope":"insider"},{"id":8820621,"accession":"0001209191-11-062937","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001209191-11-062937","line_url":"/filing/0001209191-11-062937#line-2","is_derivative":false,"issuer_cik":"0001139814","issuer_name":"ENDOCYTE INC","issuer_ticker":"ECYT","issuer_name_source":null,"issuer_url":"/issuer/0001139814","owner_cik":null,"owner_name":"Sanderling VI Beteiligungs GmbH & Co KG; SANDERLING V BIOMEDICAL CO INVESTMENT FUND LP; Sanderling Venture Partners V Co Investment Fund, LP; Sanderling VI Limited Partnership; SANDERLING V LTD PARTNERSHIP; SANDERLING V BIOMEDICAL LP; Sanderling V Strategic Exit Fund LP; SANDERLING V BETEILIGUNGS GMBH & CO KG; Sanderling Venture Partners V, LP; Sanderling Venture Partners VI Co Investment Fund LP","owner_display_name":"Sanderling VI Beteiligungs GmbH & Co KG","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":10,"other_reporting_owners":9,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":217800.0,"shares_display":"217,800","price_per_share":3.16,"price_display":"3.16","price_state":"stated","total_value":688248.0,"total_display":"688,248.00","total_whole":"688,248","shares_owned_after":871461.0,"shares_owned_after_display":"871,461","ownership_form":"I","is_10b5_1":null,"transaction_date":"2011-12-21","filed_date":"2011-12-22","scope":"insider"},{"id":9268028,"accession":"0001209191-12-003316","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001209191-12-003316","line_url":"/filing/0001209191-12-003316#line-1","is_derivative":false,"issuer_cik":"0001512540","issuer_name":"ENDOCYTE INC","issuer_ticker":"ECYT","issuer_name_source":null,"issuer_url":"/issuer/0001512540","owner_cik":null,"owner_name":"SANDERLING V BETEILIGUNGS GMBH & CO KG; SANDERLING V BIOMEDICAL CO INVESTMENT FUND LP; SANDERLING V BIOMEDICAL LP; SANDERLING V LTD PARTNERSHIP; Sanderling V Strategic Exit Fund LP; Sanderling VI Beteiligungs GmbH & Co KG; Sanderling VI Limited Partnership; Sanderling Venture Partners V Co Investment Fund, LP; Sanderling Venture Partners V, LP; Sanderling Venture Partners VI Co Investment Fund LP","owner_display_name":"SANDERLING V BETEILIGUNGS GMBH & CO KG","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":10,"other_reporting_owners":9,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":197800.0,"shares_display":"197,800","price_per_share":3.2,"price_display":"3.20","price_state":"stated","total_value":632960.0,"total_display":"632,960.00","total_whole":"632,960","shares_owned_after":633661.0,"shares_owned_after_display":"633,661","ownership_form":"I","is_10b5_1":null,"transaction_date":"2011-12-20","filed_date":"2012-01-11","scope":"insider"},{"id":8820619,"accession":"0001209191-11-062937","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001209191-11-062937","line_url":"/filing/0001209191-11-062937#line-1","is_derivative":false,"issuer_cik":"0001139814","issuer_name":"ENDOCYTE INC","issuer_ticker":"ECYT","issuer_name_source":null,"issuer_url":"/issuer/0001139814","owner_cik":null,"owner_name":"Sanderling VI Beteiligungs GmbH & Co KG; SANDERLING V BIOMEDICAL CO INVESTMENT FUND LP; Sanderling Venture Partners V Co Investment Fund, LP; Sanderling VI Limited Partnership; SANDERLING V LTD PARTNERSHIP; SANDERLING V BIOMEDICAL LP; Sanderling V Strategic Exit Fund LP; SANDERLING V BETEILIGUNGS GMBH & CO KG; Sanderling Venture Partners V, LP; Sanderling Venture Partners VI Co Investment Fund LP","owner_display_name":"Sanderling VI Beteiligungs GmbH & Co KG","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":10,"other_reporting_owners":9,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":217800.0,"shares_display":"217,800","price_per_share":3.2,"price_display":"3.20","price_state":"stated","total_value":696960.0,"total_display":"696,960.00","total_whole":"696,960","shares_owned_after":653661.0,"shares_owned_after_display":"653,661","ownership_form":"I","is_10b5_1":null,"transaction_date":"2011-12-20","filed_date":"2011-12-22","scope":"insider"},{"id":9121539,"accession":"0001181431-11-009279","txn_seq":14,"anchor":"line-14","filing_url":"/filing/0001181431-11-009279","line_url":"/filing/0001181431-11-009279#line-14","is_derivative":false,"issuer_cik":"0001306695","issuer_name":"Pacira Pharmaceuticals, Inc.","issuer_ticker":"PCRX","issuer_name_source":null,"issuer_url":"/issuer/0001306695","owner_cik":null,"owner_name":"Sanderling Ventures Management VI; Sanderling Venture Partners VI Co Investment Fund LP; Sanderling VI Beteiligungs GmbH & Co KG; Sanderling VI Limited Partnership; Sanderling Venture Partners VI LP","owner_display_name":"Sanderling Ventures Management VI","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":5,"other_reporting_owners":4,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":46379.0,"shares_display":"46,379","price_per_share":7.0,"price_display":"7.00","price_state":"stated","total_value":324653.0,"total_display":"324,653.00","total_whole":"324,653","shares_owned_after":46379.0,"shares_owned_after_display":"46,379","ownership_form":"D","is_10b5_1":null,"transaction_date":"2011-02-08","filed_date":"2011-02-10","scope":"insider"},{"id":9091737,"accession":"0001181431-11-009280","txn_seq":4,"anchor":"line-4","filing_url":"/filing/0001181431-11-009280","line_url":"/filing/0001181431-11-009280","is_derivative":false,"issuer_cik":"0001306695","issuer_name":"Pacira Pharmaceuticals, Inc.","issuer_ticker":"PCRX","issuer_name_source":null,"issuer_url":"/issuer/0001306695","owner_cik":null,"owner_name":"Sanderling Ventures Management VI; Sanderling Venture Partners VI LP; Sanderling VI Limited Partnership; Sanderling VI Beteiligungs GmbH & Co KG; Sanderling Venture Partners VI Co Investment Fund LP","owner_display_name":"Sanderling Ventures Management VI","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":5,"other_reporting_owners":4,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":221478.0,"shares_display":"221,478","price_per_share":7.0,"price_display":"7.00","price_state":"stated","total_value":1550346.0,"total_display":"1,550,346.00","total_whole":"1,550,346","shares_owned_after":184131.0,"shares_owned_after_display":"184,131","ownership_form":"D","is_10b5_1":null,"transaction_date":"2011-02-08","filed_date":"2011-02-10","scope":"insider","n_lines":4},{"id":8867947,"accession":"0001209191-11-007953","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001209191-11-007953","line_url":"/filing/0001209191-11-007953#line-1","is_derivative":false,"issuer_cik":"0001139814","issuer_name":"ENDOCYTE INC","issuer_ticker":"ECYT","issuer_name_source":null,"issuer_url":"/issuer/0001139814","owner_cik":null,"owner_name":"Sanderling Venture Partners V Co Investment Fund, LP; Sanderling Venture Partners VI Co Investment Fund LP; SANDERLING V BETEILIGUNGS GMBH & CO KG; Sanderling Venture Partners V, LP; Sanderling VI Beteiligungs GmbH & Co KG; Sanderling VI Limited Partnership; SANDERLING V BIOMEDICAL CO INVESTMENT FUND LP; SANDERLING V LTD PARTNERSHIP; SANDERLING V BIOMEDICAL LP","owner_display_name":"Sanderling Venture Partners V Co Investment Fund, LP","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":9,"other_reporting_owners":8,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":785417.0,"shares_display":"785,417","price_per_share":6.0,"price_display":"6.00","price_state":"stated","total_value":4712502.0,"total_display":"4,712,502.00","total_whole":"4,712,502","shares_owned_after":785417.0,"shares_owned_after_display":"785,417","ownership_form":"I","is_10b5_1":null,"transaction_date":"2011-02-04","filed_date":"2011-02-08","scope":"insider"},{"id":4013468,"accession":"0001104659-08-051529","txn_seq":10,"anchor":"line-10","filing_url":"/filing/0001104659-08-051529","line_url":"/filing/0001104659-08-051529","is_derivative":false,"issuer_cik":"0001113784","issuer_name":"CARDIONET INC","issuer_ticker":"BEAT","issuer_name_source":null,"issuer_url":"/issuer/0001113784","owner_cik":null,"owner_name":"Sanderling VI Beteiligungs GmbH & Co KG; Sanderling Venture Partners IV, L.P.; SANDERLING V BIOMEDICAL CO INVESTMENT FUND LP; Sanderling Venture Partners V Co Investment Fund, LP; Sanderling VI Limited Partnership; SANDERLING V LTD PARTNERSHIP; Sanderling Ventures Management VI; SANDERLING VENTURES MANAGEMENT V; SANDERLING V BETEILIGUNGS GMBH & CO KG; Sanderling Venture Partners VI Co Investment Fund LP","owner_display_name":"Sanderling VI Beteiligungs GmbH & Co KG","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":10,"other_reporting_owners":9,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":610444.0,"shares_display":"610,444","price_per_share":26.5,"price_display":"26.50","price_state":"stated","total_value":16176766.0,"total_display":"16,176,766.00","total_whole":"16,176,766","shares_owned_after":318705.0,"shares_owned_after_display":"318,705","ownership_form":"D","is_10b5_1":null,"transaction_date":"2008-08-06","filed_date":"2008-08-08","scope":"insider","n_lines":10}],"collapsed":true,"next_cursor":null,"ledger_fault":false,"count":{"value":0,"kind":"exact"},"open_market_only":false,"composition":{"kind":"exact","rows":[{"code":"P","label":"Open-market purchase","n":0,"open_market":true},{"code":"S","label":"Open-market sale","n":0,"open_market":true},{"code":"M","label":"Option exercise","n":0,"open_market":false},{"code":"A","label":"Grant or award","n":0,"open_market":false},{"code":"F","label":"Tax withholding","n":0,"open_market":false},{"code":"D","label":"Disposition to the issuer","n":0,"open_market":false},{"code":"X","label":"In-the-money option exercise","n":0,"open_market":false}],"total":0},"affiliations":[{"type":"issuer","type_label":"ISSUER","cik":"0001534133","name":"CalciMedica, Inc.","url":"/issuer/0001534133","role":"Ten percent owner","n_filings":1,"first_seen":"2024-11-05","last_seen":"2024-11-05"},{"type":"issuer","type_label":"ISSUER","cik":"0001396814","name":"Pacira Pharmaceuticals, Inc.","url":"/issuer/0001396814","role":"Director, Ten percent owner","n_filings":7,"first_seen":"2011-02-10","last_seen":"2013-04-15"},{"type":"issuer","type_label":"ISSUER","cik":"0001235007","name":"ENDOCYTE INC","url":"/issuer/0001235007","role":"Ten percent owner","n_filings":3,"first_seen":"2011-02-08","last_seen":"2012-01-11"},{"type":"issuer","type_label":"ISSUER","cik":"0001113784","name":"CARDIONET INC","url":"/issuer/0001113784","role":"Ten percent owner","n_filings":1,"first_seen":"2008-08-08","last_seen":"2008-08-08"}],"order_statement":"Newest transaction date first, id breaking the tie.","canonical_url":"https://ebomi.com/insider/0001429282","retrieved_at":"2026-08-23T00:02:51+00:00","coverage":{"filings":1506293,"transactions":4290787,"issuers":28597,"insiders":152303,"first_filed_date":"2003-06-30","last_filed_date":"2026-08-21","last_ingest":"2026-08-22T05:23:40.159918+00:00","counts_are":{"filings":"estimate","transactions":"estimate","issuers":"estimate","insiders":"estimate"},"source":"SEC EDGAR Form 4 filings, parsed by ebomi","fault":false},"license":{"underlying_records":"US SEC filings are public records of the United States government and are not subject to copyright. The transactional facts in them are not ours to license.","this_presentation":"The parsing, normalisation, curation, and presentation are ebomi's own work.","grant":"undecided","grant_note":"The open licence for ebomi's own layer is an open owner decision (SPEC-20260731T1159Z open question 3: CC BY 4.0 or CC0 with a citation request). Until it is taken, no grant is asserted here.","citation_request":"Balogh, A. Insider trading. Scientific Data 10, 237 (2023)","url":"https://ebomi.com/license"},"fair_use":{"policy":"These JSON endpoints are open and unauthenticated. Please read them at a human pace, identify your client in the User-Agent header, and use the published dataset for bulk work rather than crawling page by page.","bulk_alternative":"doi:10.1038/s41597-023-02147-6"}}